<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/stylesheet.xsl" type="text/xsl"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://feeds.transistor.fm/hard-drugs" title="MP3 Audio"/>
    <atom:link rel="hub" href="https://pubsubhubbub.appspot.com/"/>
    <podcast:podping usesPodping="true"/>
    <title>Hard Drugs</title>
    <generator>Transistor (https://transistor.fm)</generator>
    <itunes:new-feed-url>https://feeds.transistor.fm/hard-drugs</itunes:new-feed-url>
    <description>Hard Drugs is a show by Saloni Dattani and Jacob Trefethen about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most. It is brought to you by Works in Progress and Coefficient Giving.</description>
    <copyright>Works in Progress Magazine © 2025</copyright>
    <podcast:guid>2287a96f-7a9d-5f15-8a3f-69bbcdd40382</podcast:guid>
    <podcast:locked owner="wip-podcasts@stripe.com">no</podcast:locked>
    <itunes:applepodcastsverify>c7cb34b0-4532-11f0-9fda-c5bb272bc87f</itunes:applepodcastsverify>
    <podcast:trailer pubdate="Mon, 09 Jun 2025 12:59:56 +0100" url="https://media.transistor.fm/a0398da8/3215e0da.mp3" length="2400175" type="audio/mpeg">Coming soon: Hard Drugs</podcast:trailer>
    <language>en</language>
    <pubDate>Wed, 04 Mar 2026 11:29:35 +0000</pubDate>
    <lastBuildDate>Wed, 04 Mar 2026 11:30:24 +0000</lastBuildDate>
    <link>https://harddrugs.worksinprogress.co/</link>
    <image>
      <url>https://img.transistorcdn.com/S3IMMQ2cKxgY7Dp3uPnqWHv9j12AIYskpat0dfBBAjc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NzI3/YzY3Yzg1MDQzY2U2/Zjk5MTRlZjI4NjU3/NTgzOC5wbmc.jpg</url>
      <title>Hard Drugs</title>
      <link>https://harddrugs.worksinprogress.co/</link>
    </image>
    <itunes:category text="Science"/>
    <itunes:category text="Health &amp; Fitness">
      <itunes:category text="Medicine"/>
    </itunes:category>
    <itunes:type>episodic</itunes:type>
    <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
    <itunes:image href="https://img.transistorcdn.com/S3IMMQ2cKxgY7Dp3uPnqWHv9j12AIYskpat0dfBBAjc/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NzI3/YzY3Yzg1MDQzY2U2/Zjk5MTRlZjI4NjU3/NTgzOC5wbmc.jpg"/>
    <itunes:summary>Hard Drugs is a show by Saloni Dattani and Jacob Trefethen about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most. It is brought to you by Works in Progress and Coefficient Giving.</itunes:summary>
    <itunes:subtitle>Hard Drugs is a show by Saloni Dattani and Jacob Trefethen about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most.</itunes:subtitle>
    <itunes:keywords>Medicine, Global Health, Science, Technology</itunes:keywords>
    <itunes:owner>
      <itunes:name>Works in Progress &amp; Open Philanthropy</itunes:name>
    </itunes:owner>
    <itunes:complete>No</itunes:complete>
    <itunes:explicit>No</itunes:explicit>
    <item>
      <title>Should everyone be taking statins?</title>
      <itunes:episode>9</itunes:episode>
      <podcast:episode>9</podcast:episode>
      <itunes:title>Should everyone be taking statins?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">c8a09deb-1429-4b80-ab30-693d7791c696</guid>
      <link>https://share.transistor.fm/s/b19b3b4a</link>
      <description>
        <![CDATA[<p>Heart disease is the leading cause of death worldwide, but it’s also one of medicine’s biggest success stories. Since the 1950s, the risk of dying from cardiovascular disease has fallen dramatically, thanks to public health efforts, emergency care, medical innovation, and surgeries.</p><p>In this episode, Jacob and Saloni explore the cholesterol revolution: from statins discovered in fungi to new drugs that cut LDL cholesterol by 60% and last for months, driven by breakthroughs in genetics, monoclonal antibodies, RNA therapies, and modern medicinal chemistry. They talk about how cholesterol travels through the bloodstream, how it causes atherosclerosis and heart disease, and why it took nearly a century for scientists to form the consensus that lowering cholesterol saves lives.</p><p>Hard Drugs is a podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters: <br>0:00:00 Introduction<br>13:35 The decline in heart disease mortality<br>31:02 Surprising facts about cholesterol<br>55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol<br>1:22:15 How cholesterol works<br>1:30:40 The discovery of statins<br>1:48:44 Should everyone be on statins?<br>1:57:10 PCSK9 drugs and beyond<br>2:22:56 Summary </p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Coefficient Giving</p><p>Correction: In the episode, Saloni makes an error in converting the number of heartbeats per lifetime. It is roughly 2.5 billion beats, not a trillion.</p><p>Books</p><ul><li>Daniel Steinberg (2007) The Cholesterol Wars.</li><li>Jie Jack Li (2009) Triumph of the Heart: The Story of Statins.<p></p></li></ul><p>Blog posts</p><ul><li>James Stein (2025) Lipid and lipoprotein basics series. <a href="https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics">https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics</a> <p></p></li></ul><p>Articles</p><ul><li>Akira Endo (2017) Discovery and Development of Statins <a href="https://doi.org/10.1177/1934578X1701200801">https://doi.org/10.1177/1934578X1701200801</a> </li><li>Joseph L Goldstein, Michael S Brown (2010) History of discovery: The LDL receptor. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/">https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/</a> </li><li>Patty W. Siri-Tarino and Ronald M. Krauss (2016) The early years of lipoprotein research: from discovery to clinical application <a href="https://pubmed.ncbi.nlm.nih.gov/27474223/">https://pubmed.ncbi.nlm.nih.gov/27474223/</a> </li><li>Eun Ji Kim and Anthony S. Wierzbicki (2020) The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease <a href="https://pubmed.ncbi.nlm.nih.gov/32537117/">https://pubmed.ncbi.nlm.nih.gov/32537117/</a> </li><li>Patrick W. Siri-Tarino et al. (2010) Saturated fat, carbohydrate, and cardiovascular disease.<a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312?utm_source=chatgpt.com"> </a><a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312">https://www.pnas.org/doi/10.1073/pnas.94.9.4312</a></li><li>Saloni Dattani (2025) Death rates from cardiovascular disease have fallen dramatically — what were the breakthroughs behind this?<a href="https://ourworldindata.org/cardiovascular-deaths-decline?utm_source=chatgpt.com"> </a><a href="https://ourworldindata.org/cardiovascular-deaths-decline">https://ourworldindata.org/cardiovascular-deaths-decline</a></li><li>Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.<a href="https://www.thelancet.com/article/S0140-6736%2810%2961350-5/fulltext?utm_source=chatgpt.com"> </a><a href="https://doi.org/10.1016/S0140-6736(10)61350-5">https://doi.org/10.1016/S0140-6736(10)61350-5</a></li><li>E. J. Mills et al. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.<a href="https://pubmed.ncbi.nlm.nih.gov/20934984/"> https://pubmed.ncbi.nlm.nih.gov/20934984/</a></li><li>Julia Brandts and Kausik K. Ray (2023) Novel and future lipid-modulating therapies for the prevention of cardiovascular disease.  <a href="https://www.nature.com/articles/s41569-023-00860-8">https://www.nature.com/articles/s41569-023-00860-8</a></li></ul><p>Videos</p><ul><li>Ninja Nerd (2018) Lipoprotein metabolism <a href="https://www.youtube.com/watch?v=wQY0xpwqPfQ">https://www.youtube.com/watch?v=wQY0xpwqPfQ</a> <p></p></li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Heart disease is the leading cause of death worldwide, but it’s also one of medicine’s biggest success stories. Since the 1950s, the risk of dying from cardiovascular disease has fallen dramatically, thanks to public health efforts, emergency care, medical innovation, and surgeries.</p><p>In this episode, Jacob and Saloni explore the cholesterol revolution: from statins discovered in fungi to new drugs that cut LDL cholesterol by 60% and last for months, driven by breakthroughs in genetics, monoclonal antibodies, RNA therapies, and modern medicinal chemistry. They talk about how cholesterol travels through the bloodstream, how it causes atherosclerosis and heart disease, and why it took nearly a century for scientists to form the consensus that lowering cholesterol saves lives.</p><p>Hard Drugs is a podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters: <br>0:00:00 Introduction<br>13:35 The decline in heart disease mortality<br>31:02 Surprising facts about cholesterol<br>55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol<br>1:22:15 How cholesterol works<br>1:30:40 The discovery of statins<br>1:48:44 Should everyone be on statins?<br>1:57:10 PCSK9 drugs and beyond<br>2:22:56 Summary </p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Coefficient Giving</p><p>Correction: In the episode, Saloni makes an error in converting the number of heartbeats per lifetime. It is roughly 2.5 billion beats, not a trillion.</p><p>Books</p><ul><li>Daniel Steinberg (2007) The Cholesterol Wars.</li><li>Jie Jack Li (2009) Triumph of the Heart: The Story of Statins.<p></p></li></ul><p>Blog posts</p><ul><li>James Stein (2025) Lipid and lipoprotein basics series. <a href="https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics">https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics</a> <p></p></li></ul><p>Articles</p><ul><li>Akira Endo (2017) Discovery and Development of Statins <a href="https://doi.org/10.1177/1934578X1701200801">https://doi.org/10.1177/1934578X1701200801</a> </li><li>Joseph L Goldstein, Michael S Brown (2010) History of discovery: The LDL receptor. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/">https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/</a> </li><li>Patty W. Siri-Tarino and Ronald M. Krauss (2016) The early years of lipoprotein research: from discovery to clinical application <a href="https://pubmed.ncbi.nlm.nih.gov/27474223/">https://pubmed.ncbi.nlm.nih.gov/27474223/</a> </li><li>Eun Ji Kim and Anthony S. Wierzbicki (2020) The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease <a href="https://pubmed.ncbi.nlm.nih.gov/32537117/">https://pubmed.ncbi.nlm.nih.gov/32537117/</a> </li><li>Patrick W. Siri-Tarino et al. (2010) Saturated fat, carbohydrate, and cardiovascular disease.<a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312?utm_source=chatgpt.com"> </a><a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312">https://www.pnas.org/doi/10.1073/pnas.94.9.4312</a></li><li>Saloni Dattani (2025) Death rates from cardiovascular disease have fallen dramatically — what were the breakthroughs behind this?<a href="https://ourworldindata.org/cardiovascular-deaths-decline?utm_source=chatgpt.com"> </a><a href="https://ourworldindata.org/cardiovascular-deaths-decline">https://ourworldindata.org/cardiovascular-deaths-decline</a></li><li>Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.<a href="https://www.thelancet.com/article/S0140-6736%2810%2961350-5/fulltext?utm_source=chatgpt.com"> </a><a href="https://doi.org/10.1016/S0140-6736(10)61350-5">https://doi.org/10.1016/S0140-6736(10)61350-5</a></li><li>E. J. Mills et al. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.<a href="https://pubmed.ncbi.nlm.nih.gov/20934984/"> https://pubmed.ncbi.nlm.nih.gov/20934984/</a></li><li>Julia Brandts and Kausik K. Ray (2023) Novel and future lipid-modulating therapies for the prevention of cardiovascular disease.  <a href="https://www.nature.com/articles/s41569-023-00860-8">https://www.nature.com/articles/s41569-023-00860-8</a></li></ul><p>Videos</p><ul><li>Ninja Nerd (2018) Lipoprotein metabolism <a href="https://www.youtube.com/watch?v=wQY0xpwqPfQ">https://www.youtube.com/watch?v=wQY0xpwqPfQ</a> <p></p></li></ul>]]>
      </content:encoded>
      <pubDate>Fri, 27 Feb 2026 10:49:29 +0000</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/b19b3b4a/31dc395b.mp3" length="252989805" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>10487</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Heart disease is the leading cause of death worldwide, but it’s also one of medicine’s biggest success stories. Since the 1950s, the risk of dying from cardiovascular disease has fallen dramatically, thanks to public health efforts, emergency care, medical innovation, and surgeries.</p><p>In this episode, Jacob and Saloni explore the cholesterol revolution: from statins discovered in fungi to new drugs that cut LDL cholesterol by 60% and last for months, driven by breakthroughs in genetics, monoclonal antibodies, RNA therapies, and modern medicinal chemistry. They talk about how cholesterol travels through the bloodstream, how it causes atherosclerosis and heart disease, and why it took nearly a century for scientists to form the consensus that lowering cholesterol saves lives.</p><p>Hard Drugs is a podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters: <br>0:00:00 Introduction<br>13:35 The decline in heart disease mortality<br>31:02 Surprising facts about cholesterol<br>55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol<br>1:22:15 How cholesterol works<br>1:30:40 The discovery of statins<br>1:48:44 Should everyone be on statins?<br>1:57:10 PCSK9 drugs and beyond<br>2:22:56 Summary </p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Coefficient Giving</p><p>Correction: In the episode, Saloni makes an error in converting the number of heartbeats per lifetime. It is roughly 2.5 billion beats, not a trillion.</p><p>Books</p><ul><li>Daniel Steinberg (2007) The Cholesterol Wars.</li><li>Jie Jack Li (2009) Triumph of the Heart: The Story of Statins.<p></p></li></ul><p>Blog posts</p><ul><li>James Stein (2025) Lipid and lipoprotein basics series. <a href="https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics">https://jamesstein18.substack.com/p/part-i-lipid-and-lipoprotein-basics</a> <p></p></li></ul><p>Articles</p><ul><li>Akira Endo (2017) Discovery and Development of Statins <a href="https://doi.org/10.1177/1934578X1701200801">https://doi.org/10.1177/1934578X1701200801</a> </li><li>Joseph L Goldstein, Michael S Brown (2010) History of discovery: The LDL receptor. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/">https://pmc.ncbi.nlm.nih.gov/articles/PMC2740366/</a> </li><li>Patty W. Siri-Tarino and Ronald M. Krauss (2016) The early years of lipoprotein research: from discovery to clinical application <a href="https://pubmed.ncbi.nlm.nih.gov/27474223/">https://pubmed.ncbi.nlm.nih.gov/27474223/</a> </li><li>Eun Ji Kim and Anthony S. Wierzbicki (2020) The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease <a href="https://pubmed.ncbi.nlm.nih.gov/32537117/">https://pubmed.ncbi.nlm.nih.gov/32537117/</a> </li><li>Patrick W. Siri-Tarino et al. (2010) Saturated fat, carbohydrate, and cardiovascular disease.<a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312?utm_source=chatgpt.com"> </a><a href="https://www.pnas.org/doi/10.1073/pnas.94.9.4312">https://www.pnas.org/doi/10.1073/pnas.94.9.4312</a></li><li>Saloni Dattani (2025) Death rates from cardiovascular disease have fallen dramatically — what were the breakthroughs behind this?<a href="https://ourworldindata.org/cardiovascular-deaths-decline?utm_source=chatgpt.com"> </a><a href="https://ourworldindata.org/cardiovascular-deaths-decline">https://ourworldindata.org/cardiovascular-deaths-decline</a></li><li>Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.<a href="https://www.thelancet.com/article/S0140-6736%2810%2961350-5/fulltext?utm_source=chatgpt.com"> </a><a href="https://doi.org/10.1016/S0140-6736(10)61350-5">https://doi.org/10.1016/S0140-6736(10)61350-5</a></li><li>E. J. Mills et al. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.<a href="https://pubmed.ncbi.nlm.nih.gov/20934984/"> https://pubmed.ncbi.nlm.nih.gov/20934984/</a></li><li>Julia Brandts and Kausik K. Ray (2023) Novel and future lipid-modulating therapies for the prevention of cardiovascular disease.  <a href="https://www.nature.com/articles/s41569-023-00860-8">https://www.nature.com/articles/s41569-023-00860-8</a></li></ul><p>Videos</p><ul><li>Ninja Nerd (2018) Lipoprotein metabolism <a href="https://www.youtube.com/watch?v=wQY0xpwqPfQ">https://www.youtube.com/watch?v=wQY0xpwqPfQ</a> <p></p></li></ul>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, Global Health, Science, Technology</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/b19b3b4a/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>The first cancer vaccine</title>
      <itunes:episode>8</itunes:episode>
      <podcast:episode>8</podcast:episode>
      <itunes:title>The first cancer vaccine</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b067ed1b-70ca-49ea-b6bc-f2376b71388a</guid>
      <link>https://share.transistor.fm/s/0db779fc</link>
      <description>
        <![CDATA[<p>Hepatitis B is a tiny virus that causes hundreds of thousands of deaths from liver disease and cancer each year. The vaccine against it became the first of many milestones: it was the first viral protein subunit vaccine, the first recombinant vaccine, and the first vaccine to prevent a type of cancer. </p><p>In this episode, Jacob and Saloni follow the trail of strange jaundice outbreaks that scientists traced to a stealthy liver virus, how scientists turned one viral surface protein into a lifesaving shot for newborns, and how it was all built upon breakthroughs in immunology.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p><br></p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters:<br>0:00:00 Introducing the hepatitis B vaccine<br>0:15:46 The mysterious trail of jaundice outbreaks<br>0:28:03 How a tiny virus causes cirrhosis and liver cancer<br>0:53:19 Maurice Hilleman's purified hep B vaccine<br>1:17:36 Turning the hep B vaccine recombinant<br>1:29:14 The impact of hep B vaccination<br>1:39:27 The 19th century battle for immunology<br>2:01:34 How the body makes an almost infinite number of antibodies<br>2:30:57 How subunit vaccines took over<br>2:45:33 Conclusion</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Books:</p><ul><li>Paul Offit (2007) Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases</li><li>Arthur M Silverstein (2009) A history of immunology</li><li>Ronald W Ellis (1993) Hepatitis B Vaccines in Clinical Practice</li><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Articles:</p><ul><li>Timothy M. Block et al. (2016) A historical perspective on the discovery and elucidation of the hepatitis B virus <a href="https://doi.org/10.1016/j.antiviral.2016.04.012">https://doi.org/10.1016/j.antiviral.2016.04.012</a> </li><li>Naijuan Yao et al. (2022) Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis <a href="https://doi.org/10.1111/aogs.14448">https://doi.org/10.1111/aogs.14448</a></li><li>Jill Koshiol et al. (2019) Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/">https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/</a> </li><li>William J. McAleer et al. (1984) Human hepatitis B vaccine from recombinant yeast <a href="https://doi.org/10.1038/307178a0">https://doi.org/10.1038/307178a0</a> </li><li>Chunfeng Qu et al. (2014) Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial <a href="https://doi.org/10.1371/journal.pmed.1001774">https://doi.org/10.1371/journal.pmed.1001774</a> </li><li>Anthony R Rees (2020) Understanding the human antibody repertoire <a href="https://doi.org/10.1080/19420862.2020.1729683">https://doi.org/10.1080/19420862.2020.1729683</a> </li></ul><p>Correction: Urea was mentioned as a protein, but is actually the product of a protein breakdown process, not a protein itself.</p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Hepatitis B is a tiny virus that causes hundreds of thousands of deaths from liver disease and cancer each year. The vaccine against it became the first of many milestones: it was the first viral protein subunit vaccine, the first recombinant vaccine, and the first vaccine to prevent a type of cancer. </p><p>In this episode, Jacob and Saloni follow the trail of strange jaundice outbreaks that scientists traced to a stealthy liver virus, how scientists turned one viral surface protein into a lifesaving shot for newborns, and how it was all built upon breakthroughs in immunology.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p><br></p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters:<br>0:00:00 Introducing the hepatitis B vaccine<br>0:15:46 The mysterious trail of jaundice outbreaks<br>0:28:03 How a tiny virus causes cirrhosis and liver cancer<br>0:53:19 Maurice Hilleman's purified hep B vaccine<br>1:17:36 Turning the hep B vaccine recombinant<br>1:29:14 The impact of hep B vaccination<br>1:39:27 The 19th century battle for immunology<br>2:01:34 How the body makes an almost infinite number of antibodies<br>2:30:57 How subunit vaccines took over<br>2:45:33 Conclusion</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Books:</p><ul><li>Paul Offit (2007) Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases</li><li>Arthur M Silverstein (2009) A history of immunology</li><li>Ronald W Ellis (1993) Hepatitis B Vaccines in Clinical Practice</li><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Articles:</p><ul><li>Timothy M. Block et al. (2016) A historical perspective on the discovery and elucidation of the hepatitis B virus <a href="https://doi.org/10.1016/j.antiviral.2016.04.012">https://doi.org/10.1016/j.antiviral.2016.04.012</a> </li><li>Naijuan Yao et al. (2022) Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis <a href="https://doi.org/10.1111/aogs.14448">https://doi.org/10.1111/aogs.14448</a></li><li>Jill Koshiol et al. (2019) Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/">https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/</a> </li><li>William J. McAleer et al. (1984) Human hepatitis B vaccine from recombinant yeast <a href="https://doi.org/10.1038/307178a0">https://doi.org/10.1038/307178a0</a> </li><li>Chunfeng Qu et al. (2014) Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial <a href="https://doi.org/10.1371/journal.pmed.1001774">https://doi.org/10.1371/journal.pmed.1001774</a> </li><li>Anthony R Rees (2020) Understanding the human antibody repertoire <a href="https://doi.org/10.1080/19420862.2020.1729683">https://doi.org/10.1080/19420862.2020.1729683</a> </li></ul><p>Correction: Urea was mentioned as a protein, but is actually the product of a protein breakdown process, not a protein itself.</p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </content:encoded>
      <pubDate>Mon, 22 Dec 2025 16:34:45 +0000</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/0db779fc/73e9fe8a.mp3" length="171687086" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>10727</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Hepatitis B is a tiny virus that causes hundreds of thousands of deaths from liver disease and cancer each year. The vaccine against it became the first of many milestones: it was the first viral protein subunit vaccine, the first recombinant vaccine, and the first vaccine to prevent a type of cancer. </p><p>In this episode, Jacob and Saloni follow the trail of strange jaundice outbreaks that scientists traced to a stealthy liver virus, how scientists turned one viral surface protein into a lifesaving shot for newborns, and how it was all built upon breakthroughs in immunology.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p><br></p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Chapters:<br>0:00:00 Introducing the hepatitis B vaccine<br>0:15:46 The mysterious trail of jaundice outbreaks<br>0:28:03 How a tiny virus causes cirrhosis and liver cancer<br>0:53:19 Maurice Hilleman's purified hep B vaccine<br>1:17:36 Turning the hep B vaccine recombinant<br>1:29:14 The impact of hep B vaccination<br>1:39:27 The 19th century battle for immunology<br>2:01:34 How the body makes an almost infinite number of antibodies<br>2:30:57 How subunit vaccines took over<br>2:45:33 Conclusion</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Books:</p><ul><li>Paul Offit (2007) Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases</li><li>Arthur M Silverstein (2009) A history of immunology</li><li>Ronald W Ellis (1993) Hepatitis B Vaccines in Clinical Practice</li><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Articles:</p><ul><li>Timothy M. Block et al. (2016) A historical perspective on the discovery and elucidation of the hepatitis B virus <a href="https://doi.org/10.1016/j.antiviral.2016.04.012">https://doi.org/10.1016/j.antiviral.2016.04.012</a> </li><li>Naijuan Yao et al. (2022) Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis <a href="https://doi.org/10.1111/aogs.14448">https://doi.org/10.1111/aogs.14448</a></li><li>Jill Koshiol et al. (2019) Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/">https://pmc.ncbi.nlm.nih.gov/articles/PMC5866222/</a> </li><li>William J. McAleer et al. (1984) Human hepatitis B vaccine from recombinant yeast <a href="https://doi.org/10.1038/307178a0">https://doi.org/10.1038/307178a0</a> </li><li>Chunfeng Qu et al. (2014) Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial <a href="https://doi.org/10.1371/journal.pmed.1001774">https://doi.org/10.1371/journal.pmed.1001774</a> </li><li>Anthony R Rees (2020) Understanding the human antibody repertoire <a href="https://doi.org/10.1080/19420862.2020.1729683">https://doi.org/10.1080/19420862.2020.1729683</a> </li></ul><p>Correction: Urea was mentioned as a protein, but is actually the product of a protein breakdown process, not a protein itself.</p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, Global Health, Science, Technology</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/0db779fc/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>The history of vaccines</title>
      <itunes:episode>7</itunes:episode>
      <podcast:episode>7</podcast:episode>
      <itunes:title>The history of vaccines</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8fcf7b80-ebe0-4985-a69a-b9ef101a8437</guid>
      <link>https://share.transistor.fm/s/8b740b88</link>
      <description>
        <![CDATA[<p>Before vaccines became routine, they were risky experiments. In this episode, Jacob and Saloni travel back to the world of smallpox, cowpox, and cow-based “vaccine farms” to see how scientists stumbled toward the first vaccines against infectious diseases: smallpox, rabies, TB, polio, and more. Through the stories of milkmaids and aristocrats, secret lab notebooks, microscopes and cell culture, they explore how trial and error turned gruesome folk practices into the science of immunization, and how it all began with a single pustule.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Gerald Geison (1995) The private science of Louis Pasteur</li><li>Thomas D. Brock (1998) Robert Koch: a life in medicine and bacteriology</li><li>Mervyn Susser and Zena Stein (2009) Eras in epidemiology : the evolution of ideas</li><li>Angela Leung (2011) Chapter: “Variolation” and vaccination in late Imperial China, ca. 1570–1911. History of vaccine development by Stanley Plotkin</li><li>Florian Horaud (2011) Chapter: Viral vaccines and cell substrate. History of vaccine development by Stanley Plotkin</li><li>Samuel Katz (2011) Chapter: The role of tissue culture in vaccine development. History of vaccine development by Stanley Plotkin</li><li>Hervé Bazin (2011) Chapter: Pasteur and the birth of vaccines made in the laboratory. History of vaccine development by Stanley Plotkin<p></p></li></ul><p>Articles:</p><ul><li>Andrew Shattock et al. (2024) Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext</a> </li><li>Saloni Dattani (2020) The story of Viktor Zhdanov <a href="https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/">https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/</a></li><li>José Esparza et al. (2020) Early smallpox vaccine manufacturing in the United States <a href="https://doi.org/10.1016/j.vaccine.2020.05.037">https://doi.org/10.1016/j.vaccine.2020.05.037</a> </li><li>Paula Gottdenker (1979) Francesco Redi and the fly experiments <a href="https://www.jstor.org/stable/44450950">https://www.jstor.org/stable/44450950</a> </li><li>Donald Angus Gillies (2016) Establishing causality in medicine and Koch’s postulates</li><li>Burt A Folkart (1993) Dr. Albert Sabin, Developer of Oral Polio Vaccine, Dies <a href="https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html">https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html</a> </li><li>Saloni Dattani (2025) Measles leaves children vulnerable to other diseases for years <a href="https://ourworldindata.org/measles-increases-disease-risk">https://ourworldindata.org/measles-increases-disease-risk</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Before vaccines became routine, they were risky experiments. In this episode, Jacob and Saloni travel back to the world of smallpox, cowpox, and cow-based “vaccine farms” to see how scientists stumbled toward the first vaccines against infectious diseases: smallpox, rabies, TB, polio, and more. Through the stories of milkmaids and aristocrats, secret lab notebooks, microscopes and cell culture, they explore how trial and error turned gruesome folk practices into the science of immunization, and how it all began with a single pustule.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Gerald Geison (1995) The private science of Louis Pasteur</li><li>Thomas D. Brock (1998) Robert Koch: a life in medicine and bacteriology</li><li>Mervyn Susser and Zena Stein (2009) Eras in epidemiology : the evolution of ideas</li><li>Angela Leung (2011) Chapter: “Variolation” and vaccination in late Imperial China, ca. 1570–1911. History of vaccine development by Stanley Plotkin</li><li>Florian Horaud (2011) Chapter: Viral vaccines and cell substrate. History of vaccine development by Stanley Plotkin</li><li>Samuel Katz (2011) Chapter: The role of tissue culture in vaccine development. History of vaccine development by Stanley Plotkin</li><li>Hervé Bazin (2011) Chapter: Pasteur and the birth of vaccines made in the laboratory. History of vaccine development by Stanley Plotkin<p></p></li></ul><p>Articles:</p><ul><li>Andrew Shattock et al. (2024) Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext</a> </li><li>Saloni Dattani (2020) The story of Viktor Zhdanov <a href="https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/">https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/</a></li><li>José Esparza et al. (2020) Early smallpox vaccine manufacturing in the United States <a href="https://doi.org/10.1016/j.vaccine.2020.05.037">https://doi.org/10.1016/j.vaccine.2020.05.037</a> </li><li>Paula Gottdenker (1979) Francesco Redi and the fly experiments <a href="https://www.jstor.org/stable/44450950">https://www.jstor.org/stable/44450950</a> </li><li>Donald Angus Gillies (2016) Establishing causality in medicine and Koch’s postulates</li><li>Burt A Folkart (1993) Dr. Albert Sabin, Developer of Oral Polio Vaccine, Dies <a href="https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html">https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html</a> </li><li>Saloni Dattani (2025) Measles leaves children vulnerable to other diseases for years <a href="https://ourworldindata.org/measles-increases-disease-risk">https://ourworldindata.org/measles-increases-disease-risk</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </content:encoded>
      <pubDate>Wed, 26 Nov 2025 12:00:00 +0000</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/8b740b88/66515042.mp3" length="183082535" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>7583</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Before vaccines became routine, they were risky experiments. In this episode, Jacob and Saloni travel back to the world of smallpox, cowpox, and cow-based “vaccine farms” to see how scientists stumbled toward the first vaccines against infectious diseases: smallpox, rabies, TB, polio, and more. Through the stories of milkmaids and aristocrats, secret lab notebooks, microscopes and cell culture, they explore how trial and error turned gruesome folk practices into the science of immunization, and how it all began with a single pustule.</p><p>Hard Drugs is a new podcast from Works in Progress and Coefficient Giving about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Gerald Geison (1995) The private science of Louis Pasteur</li><li>Thomas D. Brock (1998) Robert Koch: a life in medicine and bacteriology</li><li>Mervyn Susser and Zena Stein (2009) Eras in epidemiology : the evolution of ideas</li><li>Angela Leung (2011) Chapter: “Variolation” and vaccination in late Imperial China, ca. 1570–1911. History of vaccine development by Stanley Plotkin</li><li>Florian Horaud (2011) Chapter: Viral vaccines and cell substrate. History of vaccine development by Stanley Plotkin</li><li>Samuel Katz (2011) Chapter: The role of tissue culture in vaccine development. History of vaccine development by Stanley Plotkin</li><li>Hervé Bazin (2011) Chapter: Pasteur and the birth of vaccines made in the laboratory. History of vaccine development by Stanley Plotkin<p></p></li></ul><p>Articles:</p><ul><li>Andrew Shattock et al. (2024) Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext</a> </li><li>Saloni Dattani (2020) The story of Viktor Zhdanov <a href="https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/">https://worksinprogress.co/issue/the-story-of-viktor-zhdanov/</a></li><li>José Esparza et al. (2020) Early smallpox vaccine manufacturing in the United States <a href="https://doi.org/10.1016/j.vaccine.2020.05.037">https://doi.org/10.1016/j.vaccine.2020.05.037</a> </li><li>Paula Gottdenker (1979) Francesco Redi and the fly experiments <a href="https://www.jstor.org/stable/44450950">https://www.jstor.org/stable/44450950</a> </li><li>Donald Angus Gillies (2016) Establishing causality in medicine and Koch’s postulates</li><li>Burt A Folkart (1993) Dr. Albert Sabin, Developer of Oral Polio Vaccine, Dies <a href="https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html">https://www.latimes.com/archives/la-xpm-1993-03-04-mn-283-story.html</a> </li><li>Saloni Dattani (2025) Measles leaves children vulnerable to other diseases for years <a href="https://ourworldindata.org/measles-increases-disease-risk">https://ourworldindata.org/measles-increases-disease-risk</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Coefficient Giving</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, Science</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/8b740b88/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>Will AI solve medicine?</title>
      <itunes:episode>6</itunes:episode>
      <podcast:episode>6</podcast:episode>
      <itunes:title>Will AI solve medicine?</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">8f32975f-b1e2-4f74-83cb-40bfe124799b</guid>
      <link>https://share.transistor.fm/s/8fe3c96b</link>
      <description>
        <![CDATA[<p>Artificial intelligence is transforming how we discover and develop new medicines. But how far can it really take us? In this episode, Jacob and Saloni trace the path of drug development from discovery to testing, manufacturing, and delivery. They explore where AI could speed things up, and where it still hits the limits of biology, data, and economics. They ask what it would take, beyond algorithms, to actually cure and eradicate diseases.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Chapters:<br>0:00:00 Intro<br>0:09:56 Drug discovery<br>1:02:20 Animal models<br>1:49:09 Drug efficacy<br>2:32:56 Drug safety<br>2:58:29 Manufacturing and healthcare<br>3:43:23 R&amp;D funding<br>4:00:56 Trust and ambition<br>4:16:01 Summary</p><p>Blogposts:</p><ul><li>Claus Wilke (2025) We still can’t predict much of anything in biology <a href="https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything">https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything</a> </li><li>Elliot Hershberg (2025) What are virtual cells? <a href="https://centuryofbio.com/p/virtual-cell">https://centuryofbio.com/p/virtual-cell</a> </li><li>Jacob Trefethen (2025) Blog series. 1) What does AI progress mean for medical progress? <a href="https://blog.jacobtrefethen.com/ai-progress-medical-progress/">https://blog.jacobtrefethen.com/ai-progress-medical-progress/</a> 2) AI will not suddenly lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-san-francisco/">https://blog.jacobtrefethen.com/ai-san-francisco/</a> 3) AI could help lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-optimism/">https://blog.jacobtrefethen.com/ai-optimism/</a> </li></ul><p>Articles:</p><ul><li>Wendi Yan (2024) Discovering an antimalarial drug in Mao’s China <a href="https://www.asimov.press/p/antimalarial-drug">https://www.asimov.press/p/antimalarial-drug</a> </li><li>Jason Crawford (2020) Innovation is not linear <a href="https://worksinprogress.co/issue/innovation-is-not-linear/">https://worksinprogress.co/issue/innovation-is-not-linear/</a> </li><li>Shayla Love (2025) An ‘impossible’ disease outbreak in the Alps <a href="https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/">https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/</a> </li><li>Alex Telford (2024) Origins of the lab mouse <a href="https://www.asimov.press/p/lab-mouse">https://www.asimov.press/p/lab-mouse</a> </li><li>Jonathan Karr et al. (2012) A whole-cell computational model predicts phenotype from genotype <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/</a> </li><li>Wen-Wei Liao et al. (2023) A draft human pangenome reference <a href="https://www.nature.com/articles/s41586-023-05896-x">https://www.nature.com/articles/s41586-023-05896-x</a> </li><li>Per-Ola Carlsson (2025) Survival of transplanted allogeneic beta cells with no immunosuppression <a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822">https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822</a> </li><li>Saloni Dattani (2024) Antipsychotic medications: a timeline of innovations and remaining challenges <a href="https://ourworldindata.org/antipsychotic-medications-timeline">https://ourworldindata.org/antipsychotic-medications-timeline</a> </li><li>Saloni Dattani (2024) What was the Golden Age of antibiotics, and how can we spark a new one? <a href="https://ourworldindata.org/golden-age-antibiotics">https://ourworldindata.org/golden-age-antibiotics</a> </li></ul><p>Books:</p><ul><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Theses:</p><ul><li>Alvaro Schwalb (2025). Estimating the burden of Mycobacterium tuberculosis infection and the impact of population-wide screening for tuberculosis.</li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Minor correction: Since the 1980s, malaria challenge trials no longer involve hundreds of bites; in the past, volunteers received many bites for the exposure part of the trial rather than the challenge part.]</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Artificial intelligence is transforming how we discover and develop new medicines. But how far can it really take us? In this episode, Jacob and Saloni trace the path of drug development from discovery to testing, manufacturing, and delivery. They explore where AI could speed things up, and where it still hits the limits of biology, data, and economics. They ask what it would take, beyond algorithms, to actually cure and eradicate diseases.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Chapters:<br>0:00:00 Intro<br>0:09:56 Drug discovery<br>1:02:20 Animal models<br>1:49:09 Drug efficacy<br>2:32:56 Drug safety<br>2:58:29 Manufacturing and healthcare<br>3:43:23 R&amp;D funding<br>4:00:56 Trust and ambition<br>4:16:01 Summary</p><p>Blogposts:</p><ul><li>Claus Wilke (2025) We still can’t predict much of anything in biology <a href="https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything">https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything</a> </li><li>Elliot Hershberg (2025) What are virtual cells? <a href="https://centuryofbio.com/p/virtual-cell">https://centuryofbio.com/p/virtual-cell</a> </li><li>Jacob Trefethen (2025) Blog series. 1) What does AI progress mean for medical progress? <a href="https://blog.jacobtrefethen.com/ai-progress-medical-progress/">https://blog.jacobtrefethen.com/ai-progress-medical-progress/</a> 2) AI will not suddenly lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-san-francisco/">https://blog.jacobtrefethen.com/ai-san-francisco/</a> 3) AI could help lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-optimism/">https://blog.jacobtrefethen.com/ai-optimism/</a> </li></ul><p>Articles:</p><ul><li>Wendi Yan (2024) Discovering an antimalarial drug in Mao’s China <a href="https://www.asimov.press/p/antimalarial-drug">https://www.asimov.press/p/antimalarial-drug</a> </li><li>Jason Crawford (2020) Innovation is not linear <a href="https://worksinprogress.co/issue/innovation-is-not-linear/">https://worksinprogress.co/issue/innovation-is-not-linear/</a> </li><li>Shayla Love (2025) An ‘impossible’ disease outbreak in the Alps <a href="https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/">https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/</a> </li><li>Alex Telford (2024) Origins of the lab mouse <a href="https://www.asimov.press/p/lab-mouse">https://www.asimov.press/p/lab-mouse</a> </li><li>Jonathan Karr et al. (2012) A whole-cell computational model predicts phenotype from genotype <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/</a> </li><li>Wen-Wei Liao et al. (2023) A draft human pangenome reference <a href="https://www.nature.com/articles/s41586-023-05896-x">https://www.nature.com/articles/s41586-023-05896-x</a> </li><li>Per-Ola Carlsson (2025) Survival of transplanted allogeneic beta cells with no immunosuppression <a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822">https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822</a> </li><li>Saloni Dattani (2024) Antipsychotic medications: a timeline of innovations and remaining challenges <a href="https://ourworldindata.org/antipsychotic-medications-timeline">https://ourworldindata.org/antipsychotic-medications-timeline</a> </li><li>Saloni Dattani (2024) What was the Golden Age of antibiotics, and how can we spark a new one? <a href="https://ourworldindata.org/golden-age-antibiotics">https://ourworldindata.org/golden-age-antibiotics</a> </li></ul><p>Books:</p><ul><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Theses:</p><ul><li>Alvaro Schwalb (2025). Estimating the burden of Mycobacterium tuberculosis infection and the impact of population-wide screening for tuberculosis.</li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Minor correction: Since the 1980s, malaria challenge trials no longer involve hundreds of bites; in the past, volunteers received many bites for the exposure part of the trial rather than the challenge part.]</p>]]>
      </content:encoded>
      <pubDate>Wed, 29 Oct 2025 04:00:00 +0000</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/8fe3c96b/55e506f1.mp3" length="397156985" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>16488</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Artificial intelligence is transforming how we discover and develop new medicines. But how far can it really take us? In this episode, Jacob and Saloni trace the path of drug development from discovery to testing, manufacturing, and delivery. They explore where AI could speed things up, and where it still hits the limits of biology, data, and economics. They ask what it would take, beyond algorithms, to actually cure and eradicate diseases.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Chapters:<br>0:00:00 Intro<br>0:09:56 Drug discovery<br>1:02:20 Animal models<br>1:49:09 Drug efficacy<br>2:32:56 Drug safety<br>2:58:29 Manufacturing and healthcare<br>3:43:23 R&amp;D funding<br>4:00:56 Trust and ambition<br>4:16:01 Summary</p><p>Blogposts:</p><ul><li>Claus Wilke (2025) We still can’t predict much of anything in biology <a href="https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything">https://blog.genesmindsmachines.com/p/we-still-cant-predict-much-of-anything</a> </li><li>Elliot Hershberg (2025) What are virtual cells? <a href="https://centuryofbio.com/p/virtual-cell">https://centuryofbio.com/p/virtual-cell</a> </li><li>Jacob Trefethen (2025) Blog series. 1) What does AI progress mean for medical progress? <a href="https://blog.jacobtrefethen.com/ai-progress-medical-progress/">https://blog.jacobtrefethen.com/ai-progress-medical-progress/</a> 2) AI will not suddenly lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-san-francisco/">https://blog.jacobtrefethen.com/ai-san-francisco/</a> 3) AI could help lead to an Alzheimer’s cure <a href="https://blog.jacobtrefethen.com/ai-optimism/">https://blog.jacobtrefethen.com/ai-optimism/</a> </li></ul><p>Articles:</p><ul><li>Wendi Yan (2024) Discovering an antimalarial drug in Mao’s China <a href="https://www.asimov.press/p/antimalarial-drug">https://www.asimov.press/p/antimalarial-drug</a> </li><li>Jason Crawford (2020) Innovation is not linear <a href="https://worksinprogress.co/issue/innovation-is-not-linear/">https://worksinprogress.co/issue/innovation-is-not-linear/</a> </li><li>Shayla Love (2025) An ‘impossible’ disease outbreak in the Alps <a href="https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/">https://www.theatlantic.com/health/archive/2025/03/als-outbreak-montchavin-mystery/682096/</a> </li><li>Alex Telford (2024) Origins of the lab mouse <a href="https://www.asimov.press/p/lab-mouse">https://www.asimov.press/p/lab-mouse</a> </li><li>Jonathan Karr et al. (2012) A whole-cell computational model predicts phenotype from genotype <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3413483/</a> </li><li>Wen-Wei Liao et al. (2023) A draft human pangenome reference <a href="https://www.nature.com/articles/s41586-023-05896-x">https://www.nature.com/articles/s41586-023-05896-x</a> </li><li>Per-Ola Carlsson (2025) Survival of transplanted allogeneic beta cells with no immunosuppression <a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822">https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503822</a> </li><li>Saloni Dattani (2024) Antipsychotic medications: a timeline of innovations and remaining challenges <a href="https://ourworldindata.org/antipsychotic-medications-timeline">https://ourworldindata.org/antipsychotic-medications-timeline</a> </li><li>Saloni Dattani (2024) What was the Golden Age of antibiotics, and how can we spark a new one? <a href="https://ourworldindata.org/golden-age-antibiotics">https://ourworldindata.org/golden-age-antibiotics</a> </li></ul><p>Books:</p><ul><li>Sally Smith Hughes (2011) Genentech: The beginnings of biotech</li></ul><p>Theses:</p><ul><li>Alvaro Schwalb (2025). Estimating the burden of Mycobacterium tuberculosis infection and the impact of population-wide screening for tuberculosis.</li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Minor correction: Since the 1980s, malaria challenge trials no longer involve hundreds of bites; in the past, volunteers received many bites for the exposure part of the trial rather than the challenge part.]</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, AI</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/8fe3c96b/transcript.txt" type="text/plain"/>
      <podcast:chapters url="https://share.transistor.fm/s/8fe3c96b/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>The art of protein design with AI</title>
      <itunes:episode>5</itunes:episode>
      <podcast:episode>5</podcast:episode>
      <itunes:title>The art of protein design with AI</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">b931832b-4930-4246-a992-5a9b4b874ac2</guid>
      <link>https://share.transistor.fm/s/31e0639d</link>
      <description>
        <![CDATA[<p>What if you could design a protein never seen in nature? In this episode, Jacob and Saloni explore how researchers are using new tools like RFDiffusion, AlphaFold, and ProteinMPNN to ‘hallucinate’ entirely novel proteins: designing them from scratch to solve problems evolution hasn’t tackled. They talk about how these technologies could transform medicine, agriculture, and materials science. Along the way, they reflect on the surprising ways AI is changing the process of science itself.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> <p></p></li></ul><p>Articles:</p><ul><li>Tanja Kortemme (2024) De novo protein design—From new structures to programmable functions <a href="https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2">https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2</a> </li><li>Jie Zhu et al. (2021) Protein Assembly by Design <a href="https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308">https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308</a> <p></p></li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) Diffusion models for protein structure generation (and design) <a href="https://www.youtube.com/watch?v=OEnY2yA3jy8">https://www.youtube.com/watch?v=OEnY2yA3jy8</a> </li><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>What if you could design a protein never seen in nature? In this episode, Jacob and Saloni explore how researchers are using new tools like RFDiffusion, AlphaFold, and ProteinMPNN to ‘hallucinate’ entirely novel proteins: designing them from scratch to solve problems evolution hasn’t tackled. They talk about how these technologies could transform medicine, agriculture, and materials science. Along the way, they reflect on the surprising ways AI is changing the process of science itself.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> <p></p></li></ul><p>Articles:</p><ul><li>Tanja Kortemme (2024) De novo protein design—From new structures to programmable functions <a href="https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2">https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2</a> </li><li>Jie Zhu et al. (2021) Protein Assembly by Design <a href="https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308">https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308</a> <p></p></li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) Diffusion models for protein structure generation (and design) <a href="https://www.youtube.com/watch?v=OEnY2yA3jy8">https://www.youtube.com/watch?v=OEnY2yA3jy8</a> </li><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </content:encoded>
      <pubDate>Wed, 15 Oct 2025 04:00:00 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/31e0639d/81293002.mp3" length="58007148" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>3621</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>What if you could design a protein never seen in nature? In this episode, Jacob and Saloni explore how researchers are using new tools like RFDiffusion, AlphaFold, and ProteinMPNN to ‘hallucinate’ entirely novel proteins: designing them from scratch to solve problems evolution hasn’t tackled. They talk about how these technologies could transform medicine, agriculture, and materials science. Along the way, they reflect on the surprising ways AI is changing the process of science itself.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> <p></p></li></ul><p>Articles:</p><ul><li>Tanja Kortemme (2024) De novo protein design—From new structures to programmable functions <a href="https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2">https://www.cell.com/cell/fulltext/S0092-8674(23)01402-2</a> </li><li>Jie Zhu et al. (2021) Protein Assembly by Design <a href="https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308">https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00308</a> <p></p></li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) Diffusion models for protein structure generation (and design) <a href="https://www.youtube.com/watch?v=OEnY2yA3jy8">https://www.youtube.com/watch?v=OEnY2yA3jy8</a> </li><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, AI</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/31e0639d/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>Hacking proteins with AI</title>
      <itunes:episode>4</itunes:episode>
      <podcast:episode>4</podcast:episode>
      <itunes:title>Hacking proteins with AI</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">627100ff-5922-488a-b11e-f8309c31af9e</guid>
      <link>https://share.transistor.fm/s/954e0ef7</link>
      <description>
        <![CDATA[<p>Nature didn’t evolve all the proteins we need, but maybe artificial intelligence can help. Jacob and Saloni explore how tools like AlphaFold and ProteinMPNN are helping researchers re-engineer proteins, to make them safer, more stable, and more effective. They talk about how new technologies could help make a long-sought vaccine against Strep A, which causes scarlet fever and rheumatic heart disease, and how similar tools have already led to breakthroughs against COVID and RSV.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> </li></ul><p>Articles:</p><ul><li>Monica Jain et al. (2022) Exosite binding modulates the specificity of the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/</a> </li><li>Jakki Cooney et al. (2008) Crystal structure of C5a peptidase <a href="https://www.rcsb.org/structure/3EIF">https://www.rcsb.org/structure/3EIF</a> </li><li>Hui Li et al. (2017) Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design <a href="https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k">https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k</a> </li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Correction: The structure of RSV's prefusion F protein was initially determined by X-ray crystallography by Jason McLellan and colleagues, rather than cryo-electron microscopy, although the latter was used to visualize antibody binding and confirm its structure.]</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Nature didn’t evolve all the proteins we need, but maybe artificial intelligence can help. Jacob and Saloni explore how tools like AlphaFold and ProteinMPNN are helping researchers re-engineer proteins, to make them safer, more stable, and more effective. They talk about how new technologies could help make a long-sought vaccine against Strep A, which causes scarlet fever and rheumatic heart disease, and how similar tools have already led to breakthroughs against COVID and RSV.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> </li></ul><p>Articles:</p><ul><li>Monica Jain et al. (2022) Exosite binding modulates the specificity of the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/</a> </li><li>Jakki Cooney et al. (2008) Crystal structure of C5a peptidase <a href="https://www.rcsb.org/structure/3EIF">https://www.rcsb.org/structure/3EIF</a> </li><li>Hui Li et al. (2017) Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design <a href="https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k">https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k</a> </li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Correction: The structure of RSV's prefusion F protein was initially determined by X-ray crystallography by Jason McLellan and colleagues, rather than cryo-electron microscopy, although the latter was used to visualize antibody binding and confirm its structure.]</p>]]>
      </content:encoded>
      <pubDate>Wed, 01 Oct 2025 04:00:00 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/954e0ef7/f365ebf7.mp3" length="52489829" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>3276</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Nature didn’t evolve all the proteins we need, but maybe artificial intelligence can help. Jacob and Saloni explore how tools like AlphaFold and ProteinMPNN are helping researchers re-engineer proteins, to make them safer, more stable, and more effective. They talk about how new technologies could help make a long-sought vaccine against Strep A, which causes scarlet fever and rheumatic heart disease, and how similar tools have already led to breakthroughs against COVID and RSV.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p>Courses:</p><ul><li>EMBL-EBI. AlphaFold: A practical guide <a href="https://www.ebi.ac.uk/training/online/courses/alphafold/">https://www.ebi.ac.uk/training/online/courses/alphafold/</a> </li></ul><p>Articles:</p><ul><li>Monica Jain et al. (2022) Exosite binding modulates the specificity of the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9464890/</a> </li><li>Jakki Cooney et al. (2008) Crystal structure of C5a peptidase <a href="https://www.rcsb.org/structure/3EIF">https://www.rcsb.org/structure/3EIF</a> </li><li>Hui Li et al. (2017) Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design <a href="https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k">https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra07923k</a> </li></ul><p>Lectures:</p><ul><li>Rosetta Commons (2024) AlphaFold – ML for protein structure prediction <a href="https://www.youtube.com/watch?v=SVrn8_8aKO8">https://www.youtube.com/watch?v=SVrn8_8aKO8</a> </li><li>Rosetta Commons (2024) MPNN – ML for protein sequence design <a href="https://www.youtube.com/watch?v=6z4XmUAwdNA">https://www.youtube.com/watch?v=6z4XmUAwdNA</a> </li></ul><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Graham Bessellieu, video editor</li><li>Rachel Shu, on-site editor</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer<p></p></li></ul><p>Works in Progress &amp; Open Philanthropy</p><p>[Correction: The structure of RSV's prefusion F protein was initially determined by X-ray crystallography by Jason McLellan and colleagues, rather than cryo-electron microscopy, although the latter was used to visualize antibody binding and confirm its structure.]</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, AI, Proteins</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/954e0ef7/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>100 years of insulin in 15 minutes</title>
      <itunes:episode>3</itunes:episode>
      <podcast:episode>3</podcast:episode>
      <itunes:title>100 years of insulin in 15 minutes</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">ac187b27-5593-453b-bdef-44a940d36bc8</guid>
      <link>https://share.transistor.fm/s/45a31bae</link>
      <description>
        <![CDATA[<p>A hundred years ago, insulin was scraped from pig pancreases. Today, it’s made by bacteria in giant tanks. In the second part of a mini series on proteins, drug development and AI, Saloni tells the story of how insulin went from a crude animal extract to the first genetically-engineered drug, kickstarting the biotech industry along the way.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Genentech: The beginnings of biotech by Sally Smith Hughes<p></p></li></ul><p>Articles:</p><ul><li>FDA (2007). Celebrating a Milestone: FDA's Approval of First Genetically-Engineered Product <a href="https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf">https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf</a> </li><li>Genentech (2016). Cloning Insulin <a href="https://www.gene.com/stories/cloning-insulin">https://www.gene.com/stories/cloning-insulin</a> </li><li>Arthur Riggs (2020). Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin <a href="https://academic.oup.com/edrv/article/42/3/374/6042201">https://academic.oup.com/edrv/article/42/3/374/6042201</a> <p></p></li></ul><p>Podcasts:</p><ul><li>Novo Nordisk (Ozempic) by the Acquired podcast <a href="https://www.acquired.fm/episodes/novo-nordisk-ozempic">https://www.acquired.fm/episodes/novo-nordisk-ozempic</a> <p></p></li></ul><p><br></p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Adrian Bradley, on-site producer</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>A hundred years ago, insulin was scraped from pig pancreases. Today, it’s made by bacteria in giant tanks. In the second part of a mini series on proteins, drug development and AI, Saloni tells the story of how insulin went from a crude animal extract to the first genetically-engineered drug, kickstarting the biotech industry along the way.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Genentech: The beginnings of biotech by Sally Smith Hughes<p></p></li></ul><p>Articles:</p><ul><li>FDA (2007). Celebrating a Milestone: FDA's Approval of First Genetically-Engineered Product <a href="https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf">https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf</a> </li><li>Genentech (2016). Cloning Insulin <a href="https://www.gene.com/stories/cloning-insulin">https://www.gene.com/stories/cloning-insulin</a> </li><li>Arthur Riggs (2020). Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin <a href="https://academic.oup.com/edrv/article/42/3/374/6042201">https://academic.oup.com/edrv/article/42/3/374/6042201</a> <p></p></li></ul><p>Podcasts:</p><ul><li>Novo Nordisk (Ozempic) by the Acquired podcast <a href="https://www.acquired.fm/episodes/novo-nordisk-ozempic">https://www.acquired.fm/episodes/novo-nordisk-ozempic</a> <p></p></li></ul><p><br></p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Adrian Bradley, on-site producer</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </content:encoded>
      <pubDate>Tue, 16 Sep 2025 17:00:00 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/45a31bae/0c7a2da0.mp3" length="16887080" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>1051</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>A hundred years ago, insulin was scraped from pig pancreases. Today, it’s made by bacteria in giant tanks. In the second part of a mini series on proteins, drug development and AI, Saloni tells the story of how insulin went from a crude animal extract to the first genetically-engineered drug, kickstarting the biotech industry along the way.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li>Genentech: The beginnings of biotech by Sally Smith Hughes<p></p></li></ul><p>Articles:</p><ul><li>FDA (2007). Celebrating a Milestone: FDA's Approval of First Genetically-Engineered Product <a href="https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf">https://fda.report/media/110447/Celebrating-a-Milestone--FDA%27s-Approval-of-the-First-Genetircally-Engineered-Product.pdf</a> </li><li>Genentech (2016). Cloning Insulin <a href="https://www.gene.com/stories/cloning-insulin">https://www.gene.com/stories/cloning-insulin</a> </li><li>Arthur Riggs (2020). Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin <a href="https://academic.oup.com/edrv/article/42/3/374/6042201">https://academic.oup.com/edrv/article/42/3/374/6042201</a> <p></p></li></ul><p>Podcasts:</p><ul><li>Novo Nordisk (Ozempic) by the Acquired podcast <a href="https://www.acquired.fm/episodes/novo-nordisk-ozempic">https://www.acquired.fm/episodes/novo-nordisk-ozempic</a> <p></p></li></ul><p><br></p><p>Acknowledgements:</p><ul><li>Aria Babu, editor at Works in Progress</li><li>Adrian Bradley, on-site producer</li><li>Anna Magpie, fact-checking</li><li>Abhishaike Mahajan, cover art</li><li>Atalanta Arden-Miller, art direction</li><li>David Hackett, composer</li></ul><p>Works in Progress &amp; Open Philanthropy</p>]]>
      </itunes:summary>
      <itunes:keywords>Science, Medicine, Innovation</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/45a31bae/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>Proteins: Weird blobs that do important things</title>
      <itunes:episode>2</itunes:episode>
      <podcast:episode>2</podcast:episode>
      <itunes:title>Proteins: Weird blobs that do important things</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">9a186eff-7d89-4847-b3d5-74291933288c</guid>
      <link>https://share.transistor.fm/s/00282b05</link>
      <description>
        <![CDATA[<p>This episode kicks off a mini-series on proteins, drug development and AI. Saloni and Jacob explore the world of proteins, including how proteins fold into complex shapes, why that complexity matters and how crowded and dynamic the inside of a cell really is; and they exchange surprising statistics about proteins.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br>Books:</p><ul><li>Ron Milo and Rob Phillips. Biology by the numbers <a href="https://book.bionumbers.org/">https://book.bionumbers.org/</a> </li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure <a href="https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden">https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden</a> </li></ul><p>Articles:</p><ul><li>Niko McCarty (2023). Biology is a burrito. <a href="https://www.asimov.press/p/burrito-biology">https://www.asimov.press/p/burrito-biology</a>  </li><li>Rhiannon Morris, Katrina Black, and Elliott Stollar (2022) Uncovering protein function: from classification to complexes. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/</a> </li><li>Victor Muñoz and Michele Cerminara (2016) When fast is better: protein folding fundamentals and mechanisms from ultrafast approaches <a href="https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals">https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals</a> </li></ul><p>Image credits:</p><ul><li>Chang et al. (2012) Egg white in organic electronics. <a href="https://spie.org/news/4149-egg-white-in-organic-electronics">https://spie.org/news/4149-egg-white-in-organic-electronics</a> [diagram of egg white denaturing and cross-linking]</li><li>John Kendrew’s model of myoglobin’s structure; via Carl Ivar Branden and John Tooze (1999) Introduction to protein structure.</li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure. [diagram of amino acids and protein structure]</li><li>Ron Milo and Rob Phillips. Which is bigger, mRNA or the protein it codes for? <a href="https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/">https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/</a> [diagram of myoglobin mRNA vs protein]</li><li>Scitable (2014). Microtubules and Filaments. <a href="https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/">https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/</a> [diagram of microtubules]<p></p></li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>This episode kicks off a mini-series on proteins, drug development and AI. Saloni and Jacob explore the world of proteins, including how proteins fold into complex shapes, why that complexity matters and how crowded and dynamic the inside of a cell really is; and they exchange surprising statistics about proteins.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br>Books:</p><ul><li>Ron Milo and Rob Phillips. Biology by the numbers <a href="https://book.bionumbers.org/">https://book.bionumbers.org/</a> </li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure <a href="https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden">https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden</a> </li></ul><p>Articles:</p><ul><li>Niko McCarty (2023). Biology is a burrito. <a href="https://www.asimov.press/p/burrito-biology">https://www.asimov.press/p/burrito-biology</a>  </li><li>Rhiannon Morris, Katrina Black, and Elliott Stollar (2022) Uncovering protein function: from classification to complexes. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/</a> </li><li>Victor Muñoz and Michele Cerminara (2016) When fast is better: protein folding fundamentals and mechanisms from ultrafast approaches <a href="https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals">https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals</a> </li></ul><p>Image credits:</p><ul><li>Chang et al. (2012) Egg white in organic electronics. <a href="https://spie.org/news/4149-egg-white-in-organic-electronics">https://spie.org/news/4149-egg-white-in-organic-electronics</a> [diagram of egg white denaturing and cross-linking]</li><li>John Kendrew’s model of myoglobin’s structure; via Carl Ivar Branden and John Tooze (1999) Introduction to protein structure.</li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure. [diagram of amino acids and protein structure]</li><li>Ron Milo and Rob Phillips. Which is bigger, mRNA or the protein it codes for? <a href="https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/">https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/</a> [diagram of myoglobin mRNA vs protein]</li><li>Scitable (2014). Microtubules and Filaments. <a href="https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/">https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/</a> [diagram of microtubules]<p></p></li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 03 Sep 2025 17:00:00 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/00282b05/c100e34f.mp3" length="19090313" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>1189</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>This episode kicks off a mini-series on proteins, drug development and AI. Saloni and Jacob explore the world of proteins, including how proteins fold into complex shapes, why that complexity matters and how crowded and dynamic the inside of a cell really is; and they exchange surprising statistics about proteins.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>You can watch or listen on YouTube, Spotify, or Apple Podcasts.</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br>Books:</p><ul><li>Ron Milo and Rob Phillips. Biology by the numbers <a href="https://book.bionumbers.org/">https://book.bionumbers.org/</a> </li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure <a href="https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden">https://www.taylorfrancis.com/books/mono/10.1201/9781136969898/introduction-protein-structure-john-tooze-carl-ivar-branden</a> </li></ul><p>Articles:</p><ul><li>Niko McCarty (2023). Biology is a burrito. <a href="https://www.asimov.press/p/burrito-biology">https://www.asimov.press/p/burrito-biology</a>  </li><li>Rhiannon Morris, Katrina Black, and Elliott Stollar (2022) Uncovering protein function: from classification to complexes. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9400073/</a> </li><li>Victor Muñoz and Michele Cerminara (2016) When fast is better: protein folding fundamentals and mechanisms from ultrafast approaches <a href="https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals">https://portlandpress.com/biochemj/article/473/17/2545/49248/When-fast-is-better-protein-folding-fundamentals</a> </li></ul><p>Image credits:</p><ul><li>Chang et al. (2012) Egg white in organic electronics. <a href="https://spie.org/news/4149-egg-white-in-organic-electronics">https://spie.org/news/4149-egg-white-in-organic-electronics</a> [diagram of egg white denaturing and cross-linking]</li><li>John Kendrew’s model of myoglobin’s structure; via Carl Ivar Branden and John Tooze (1999) Introduction to protein structure.</li><li>Carl Ivar Branden and John Tooze (1999) Introduction to protein structure. [diagram of amino acids and protein structure]</li><li>Ron Milo and Rob Phillips. Which is bigger, mRNA or the protein it codes for? <a href="https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/">https://book.bionumbers.org/which-is-bigger-mrna-or-the-protein-it-codes-for/</a> [diagram of myoglobin mRNA vs protein]</li><li>Scitable (2014). Microtubules and Filaments. <a href="https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/">https://www.nature.com/scitable/topicpage/microtubules-and-filaments-14052932/</a> [diagram of microtubules]<p></p></li></ul>]]>
      </itunes:summary>
      <itunes:keywords>Science</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/00282b05/transcript.srt" type="application/x-subrip" rel="captions"/>
      <podcast:transcript url="https://share.transistor.fm/s/00282b05/transcript.txt" type="text/plain"/>
    </item>
    <item>
      <title>Lenacapavir: The miracle drug that could end AIDS</title>
      <itunes:episode>1</itunes:episode>
      <podcast:episode>1</podcast:episode>
      <itunes:title>Lenacapavir: The miracle drug that could end AIDS</itunes:title>
      <itunes:episodeType>full</itunes:episodeType>
      <guid isPermaLink="false">43cdfe81-b9a3-4d03-9c70-31a2200ee535</guid>
      <link>https://share.transistor.fm/s/a3753a45</link>
      <description>
        <![CDATA[<p>Lenacapavir is a new HIV drug that blocks infections with an efficacy rate of nearly 100%, and it could completely change the fight against HIV worldwide. Saloni and Jacob talk about the development and prospects for this new drug, as well as the history of HIV, the initial discovery of retroviruses, and how HIV was transformed from a death sentence to a manageable condition.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Chapters:</p><p>00:00 Intro <br>03:52 How was HIV discovered? Where did it come from, and how does it attack the body and cause AIDS?<br>38:10 Antiretrovirals: How did scientists develop breakthrough HIV drugs — from azidothymidine to protease inhibitors to PrEP?<br>1:51:35 How does prevention and treatment work today?<br>2:19:03 HIV’s capsid and the breakthrough of lenacapavir, the first-approved HIV capsid inhibitor<br>2:50:36 How to develop long-lasting treatments<br>3:14:45 Lenacapavir’s near 100% efficacy in clinical trials<br>3:48:40 The impact of global programs against HIV, and can we now end HIV?</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li><em>How to Survive a Plague</em> — by David France (2016). [Mentioned as a history of the science and activism against the AIDS epidemic, and the protease-inhibitor breakthrough.] <a href="https://surviveaplague.com/">https://surviveaplague.com/</a> </li><li>And the Band Played On — Randy Shilts (1987). [Mentioned as an account of the early years of AIDS.] <a href="https://us.macmillan.com/books/9780312374631/andthebandplayedon/">https://us.macmillan.com/books/9780312374631/andthebandplayedon/</a> </li><li><em>Drug development stories: From bench to bedside</em> — Elsevier (2024). [Mentioned as containing a history of the development of lenacapavir] <a href="https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8">https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8</a> <p></p></li></ul><p>Retrospectives:</p><ul><li>The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic — Samuel Broder (2015). <a href="https://doi.org/10.1016/j.antiviral.2009.10.002">https://doi.org/10.1016/j.antiviral.2009.10.002</a> </li><li>History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2 — Robert Gallo (2005). <a href="https://doi.org/10.1038/sj.onc.1208980">https://doi.org/10.1038/sj.onc.1208980</a> </li><li>A Look at Long Acting Drugs — Anne de Bruyn Kops for Open Philanthropy (2025). <a href="https://bit.ly/long-acting-drugs-op">https://bit.ly/long-acting-drugs-op</a> </li><li>How To Save Twenty Million Lives, with Dr Mark Dybul — Statecraft (2023)  <a href="https://www.statecraft.pub/p/saving-twenty-million-lives">https://www.statecraft.pub/p/saving-twenty-million-lives</a> </li><li>The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor — Redshaw et al. (2000) <a href="https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1">https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1</a> <p></p></li></ul><p>Articles:</p><ul><li>The origin of genetic diversity in HIV-1 — Smyth et al. (2012). [Mentioned as a review about HIV’s recombination, which described it as “a primitive form of sexual reproduction”] <a href="https://www.sciencedirect.com/science/article/pii/S0168170212002122">https://www.sciencedirect.com/science/article/pii/S0168170212002122</a> </li><li>PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating — Rankovic et al. (2018) <a href="https://doi.org/10.1128/JVI.00845-18">https://doi.org/10.1128/JVI.00845-18</a> </li><li>Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons — Kelley et al. (2024) <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2411858">https://www.nejm.org/doi/full/10.1056/NEJMoa2411858</a> </li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) <a href="https://www.nejm.org/doi/10.1056/NEJMoa2407001">https://www.nejm.org/doi/10.1056/NEJMoa2407001</a> </li><li>The evolution of HIV-1 and the origin of AIDS — Sharp and Hahn (2010) <a href="https://doi.org/10.1098/rstb.2010.0031">https://doi.org/10.1098/rstb.2010.0031</a> </li><li>Pathogenic mechanisms of HIV disease — Moir et al. (2011) <a href="https://doi.org/10.1146/annurev-pathol-011110-130254">https://doi.org/10.1146/annurev-pathol-011110-130254</a> </li><li>Estimating per-act HIV transmission risk: a systematic review — Patel et al. (2012) <a href="https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx">https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx</a> </li><li>The structural biology of HIV-1: mechanistic and therapeutic insights — Engelman and Cherepanov (2012) <a href="https://doi.org/10.1038/nrmicro2747">https://doi.org/10.1038/nrmicro2747</a> </li><li>Challenges and opportunities in the development of complex generic long-acting injectable drug products — O’Brien et al. (2021) <a href="https://doi.org/10.1016/j.jconrel.2021.06.017">https://doi.org/10.1016/j.jconrel.2021.06.017</a> </li><li>Making a “Miracle” HIV Medicine — Nahas (2025) <a href="https://press.asimov.com/articles/hiv-medicine">https://press.asimov.com/articles/hiv-medicine</a> </li><li>Highly active antiretroviral therapy transformed the lives of people with HIV — Dattani (2024) <a href="https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv">https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv</a> </li></ul><p><br></p><p>Videos:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) <a href="https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum">https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum</a> <p></p></li></ul><p>Image credits:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) [Multiple diagrams of HIV capsid and lenacapavir’s effect.]</li><li>Saloni Dattani; Our World in Data (2024) Highly active antiretroviral therapy transformed the lives of people with HIV. [Graph of decline in HIV/AIDS mortality after HAART was introduced.]</li><li>Engelman and Cherepanov (2012). The structural biology of HIV-1: mechanistic and therapeutic insights. [Diagram of HIV’s entry into the cell.]</li><li>Susan Moir, Tae-Wook Chun, Anthony S Fauci (2011). Pathogenic mechanisms of HIV disease. [Diagram of HIV replication rates over time, contrasting acute and chronic infection.]</li><li>Saloni Dattani, adapted from Patel et al. (2014). Estimating per-act HIV transmission risk: a systematic review. [Bar chart of risks of contracting HIV from different sources when unprotected.]</li><li>Thomas Splettstoesser under CC-BY. [Diagram of HIV’s internal structure.]</li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) [Chart of lenacapavir’s efficacy.]</li><li>Our World in Data based on Joint United Nations Programme on HIV/AIDS (2024). [Chart of global HIV deaths over time.]<p></p></li></ul><p>Acknowledgements:</p><ul><li>Douglas Chukwu, researcher at Open Philanthropy</li><li>Sanela Rankovic, Acting Instructor at the Institute for...</li></ul>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Lenacapavir is a new HIV drug that blocks infections with an efficacy rate of nearly 100%, and it could completely change the fight against HIV worldwide. Saloni and Jacob talk about the development and prospects for this new drug, as well as the history of HIV, the initial discovery of retroviruses, and how HIV was transformed from a death sentence to a manageable condition.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Chapters:</p><p>00:00 Intro <br>03:52 How was HIV discovered? Where did it come from, and how does it attack the body and cause AIDS?<br>38:10 Antiretrovirals: How did scientists develop breakthrough HIV drugs — from azidothymidine to protease inhibitors to PrEP?<br>1:51:35 How does prevention and treatment work today?<br>2:19:03 HIV’s capsid and the breakthrough of lenacapavir, the first-approved HIV capsid inhibitor<br>2:50:36 How to develop long-lasting treatments<br>3:14:45 Lenacapavir’s near 100% efficacy in clinical trials<br>3:48:40 The impact of global programs against HIV, and can we now end HIV?</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li><em>How to Survive a Plague</em> — by David France (2016). [Mentioned as a history of the science and activism against the AIDS epidemic, and the protease-inhibitor breakthrough.] <a href="https://surviveaplague.com/">https://surviveaplague.com/</a> </li><li>And the Band Played On — Randy Shilts (1987). [Mentioned as an account of the early years of AIDS.] <a href="https://us.macmillan.com/books/9780312374631/andthebandplayedon/">https://us.macmillan.com/books/9780312374631/andthebandplayedon/</a> </li><li><em>Drug development stories: From bench to bedside</em> — Elsevier (2024). [Mentioned as containing a history of the development of lenacapavir] <a href="https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8">https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8</a> <p></p></li></ul><p>Retrospectives:</p><ul><li>The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic — Samuel Broder (2015). <a href="https://doi.org/10.1016/j.antiviral.2009.10.002">https://doi.org/10.1016/j.antiviral.2009.10.002</a> </li><li>History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2 — Robert Gallo (2005). <a href="https://doi.org/10.1038/sj.onc.1208980">https://doi.org/10.1038/sj.onc.1208980</a> </li><li>A Look at Long Acting Drugs — Anne de Bruyn Kops for Open Philanthropy (2025). <a href="https://bit.ly/long-acting-drugs-op">https://bit.ly/long-acting-drugs-op</a> </li><li>How To Save Twenty Million Lives, with Dr Mark Dybul — Statecraft (2023)  <a href="https://www.statecraft.pub/p/saving-twenty-million-lives">https://www.statecraft.pub/p/saving-twenty-million-lives</a> </li><li>The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor — Redshaw et al. (2000) <a href="https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1">https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1</a> <p></p></li></ul><p>Articles:</p><ul><li>The origin of genetic diversity in HIV-1 — Smyth et al. (2012). [Mentioned as a review about HIV’s recombination, which described it as “a primitive form of sexual reproduction”] <a href="https://www.sciencedirect.com/science/article/pii/S0168170212002122">https://www.sciencedirect.com/science/article/pii/S0168170212002122</a> </li><li>PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating — Rankovic et al. (2018) <a href="https://doi.org/10.1128/JVI.00845-18">https://doi.org/10.1128/JVI.00845-18</a> </li><li>Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons — Kelley et al. (2024) <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2411858">https://www.nejm.org/doi/full/10.1056/NEJMoa2411858</a> </li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) <a href="https://www.nejm.org/doi/10.1056/NEJMoa2407001">https://www.nejm.org/doi/10.1056/NEJMoa2407001</a> </li><li>The evolution of HIV-1 and the origin of AIDS — Sharp and Hahn (2010) <a href="https://doi.org/10.1098/rstb.2010.0031">https://doi.org/10.1098/rstb.2010.0031</a> </li><li>Pathogenic mechanisms of HIV disease — Moir et al. (2011) <a href="https://doi.org/10.1146/annurev-pathol-011110-130254">https://doi.org/10.1146/annurev-pathol-011110-130254</a> </li><li>Estimating per-act HIV transmission risk: a systematic review — Patel et al. (2012) <a href="https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx">https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx</a> </li><li>The structural biology of HIV-1: mechanistic and therapeutic insights — Engelman and Cherepanov (2012) <a href="https://doi.org/10.1038/nrmicro2747">https://doi.org/10.1038/nrmicro2747</a> </li><li>Challenges and opportunities in the development of complex generic long-acting injectable drug products — O’Brien et al. (2021) <a href="https://doi.org/10.1016/j.jconrel.2021.06.017">https://doi.org/10.1016/j.jconrel.2021.06.017</a> </li><li>Making a “Miracle” HIV Medicine — Nahas (2025) <a href="https://press.asimov.com/articles/hiv-medicine">https://press.asimov.com/articles/hiv-medicine</a> </li><li>Highly active antiretroviral therapy transformed the lives of people with HIV — Dattani (2024) <a href="https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv">https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv</a> </li></ul><p><br></p><p>Videos:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) <a href="https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum">https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum</a> <p></p></li></ul><p>Image credits:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) [Multiple diagrams of HIV capsid and lenacapavir’s effect.]</li><li>Saloni Dattani; Our World in Data (2024) Highly active antiretroviral therapy transformed the lives of people with HIV. [Graph of decline in HIV/AIDS mortality after HAART was introduced.]</li><li>Engelman and Cherepanov (2012). The structural biology of HIV-1: mechanistic and therapeutic insights. [Diagram of HIV’s entry into the cell.]</li><li>Susan Moir, Tae-Wook Chun, Anthony S Fauci (2011). Pathogenic mechanisms of HIV disease. [Diagram of HIV replication rates over time, contrasting acute and chronic infection.]</li><li>Saloni Dattani, adapted from Patel et al. (2014). Estimating per-act HIV transmission risk: a systematic review. [Bar chart of risks of contracting HIV from different sources when unprotected.]</li><li>Thomas Splettstoesser under CC-BY. [Diagram of HIV’s internal structure.]</li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) [Chart of lenacapavir’s efficacy.]</li><li>Our World in Data based on Joint United Nations Programme on HIV/AIDS (2024). [Chart of global HIV deaths over time.]<p></p></li></ul><p>Acknowledgements:</p><ul><li>Douglas Chukwu, researcher at Open Philanthropy</li><li>Sanela Rankovic, Acting Instructor at the Institute for...</li></ul>]]>
      </content:encoded>
      <pubDate>Wed, 11 Jun 2025 12:00:00 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/a3753a45/2077c3f2.mp3" length="282410275" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>17626</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Lenacapavir is a new HIV drug that blocks infections with an efficacy rate of nearly 100%, and it could completely change the fight against HIV worldwide. Saloni and Jacob talk about the development and prospects for this new drug, as well as the history of HIV, the initial discovery of retroviruses, and how HIV was transformed from a death sentence to a manageable condition.</p><p>Hard Drugs is a new podcast from Works in Progress and Open Philanthropy about medical innovation presented by Saloni Dattani and Jacob Trefethen.</p><p>Chapters:</p><p>00:00 Intro <br>03:52 How was HIV discovered? Where did it come from, and how does it attack the body and cause AIDS?<br>38:10 Antiretrovirals: How did scientists develop breakthrough HIV drugs — from azidothymidine to protease inhibitors to PrEP?<br>1:51:35 How does prevention and treatment work today?<br>2:19:03 HIV’s capsid and the breakthrough of lenacapavir, the first-approved HIV capsid inhibitor<br>2:50:36 How to develop long-lasting treatments<br>3:14:45 Lenacapavir’s near 100% efficacy in clinical trials<br>3:48:40 The impact of global programs against HIV, and can we now end HIV?</p><p>Saloni’s substack newsletter: <a href="https://www.scientificdiscovery.dev/">https://www.scientificdiscovery.dev/<br></a><br></p><p>Jacob’s blog: <a href="https://blog.jacobtrefethen.com/">https://blog.jacobtrefethen.com/</a> </p><p><br></p><p>Books:</p><ul><li><em>How to Survive a Plague</em> — by David France (2016). [Mentioned as a history of the science and activism against the AIDS epidemic, and the protease-inhibitor breakthrough.] <a href="https://surviveaplague.com/">https://surviveaplague.com/</a> </li><li>And the Band Played On — Randy Shilts (1987). [Mentioned as an account of the early years of AIDS.] <a href="https://us.macmillan.com/books/9780312374631/andthebandplayedon/">https://us.macmillan.com/books/9780312374631/andthebandplayedon/</a> </li><li><em>Drug development stories: From bench to bedside</em> — Elsevier (2024). [Mentioned as containing a history of the development of lenacapavir] <a href="https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8">https://shop.elsevier.com/books/drug-discovery-stories/yu/978-0-443-23932-8</a> <p></p></li></ul><p>Retrospectives:</p><ul><li>The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic — Samuel Broder (2015). <a href="https://doi.org/10.1016/j.antiviral.2009.10.002">https://doi.org/10.1016/j.antiviral.2009.10.002</a> </li><li>History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2 — Robert Gallo (2005). <a href="https://doi.org/10.1038/sj.onc.1208980">https://doi.org/10.1038/sj.onc.1208980</a> </li><li>A Look at Long Acting Drugs — Anne de Bruyn Kops for Open Philanthropy (2025). <a href="https://bit.ly/long-acting-drugs-op">https://bit.ly/long-acting-drugs-op</a> </li><li>How To Save Twenty Million Lives, with Dr Mark Dybul — Statecraft (2023)  <a href="https://www.statecraft.pub/p/saving-twenty-million-lives">https://www.statecraft.pub/p/saving-twenty-million-lives</a> </li><li>The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor — Redshaw et al. (2000) <a href="https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1">https://link.springer.com/chapter/10.1007/978-3-642-57092-6_1</a> <p></p></li></ul><p>Articles:</p><ul><li>The origin of genetic diversity in HIV-1 — Smyth et al. (2012). [Mentioned as a review about HIV’s recombination, which described it as “a primitive form of sexual reproduction”] <a href="https://www.sciencedirect.com/science/article/pii/S0168170212002122">https://www.sciencedirect.com/science/article/pii/S0168170212002122</a> </li><li>PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating — Rankovic et al. (2018) <a href="https://doi.org/10.1128/JVI.00845-18">https://doi.org/10.1128/JVI.00845-18</a> </li><li>Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons — Kelley et al. (2024) <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2411858">https://www.nejm.org/doi/full/10.1056/NEJMoa2411858</a> </li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) <a href="https://www.nejm.org/doi/10.1056/NEJMoa2407001">https://www.nejm.org/doi/10.1056/NEJMoa2407001</a> </li><li>The evolution of HIV-1 and the origin of AIDS — Sharp and Hahn (2010) <a href="https://doi.org/10.1098/rstb.2010.0031">https://doi.org/10.1098/rstb.2010.0031</a> </li><li>Pathogenic mechanisms of HIV disease — Moir et al. (2011) <a href="https://doi.org/10.1146/annurev-pathol-011110-130254">https://doi.org/10.1146/annurev-pathol-011110-130254</a> </li><li>Estimating per-act HIV transmission risk: a systematic review — Patel et al. (2012) <a href="https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx">https://journals.lww.com/aidsonline/fulltext/2014/06190/Estimating_per_act_HIV_transmission_risk__a.14.aspx</a> </li><li>The structural biology of HIV-1: mechanistic and therapeutic insights — Engelman and Cherepanov (2012) <a href="https://doi.org/10.1038/nrmicro2747">https://doi.org/10.1038/nrmicro2747</a> </li><li>Challenges and opportunities in the development of complex generic long-acting injectable drug products — O’Brien et al. (2021) <a href="https://doi.org/10.1016/j.jconrel.2021.06.017">https://doi.org/10.1016/j.jconrel.2021.06.017</a> </li><li>Making a “Miracle” HIV Medicine — Nahas (2025) <a href="https://press.asimov.com/articles/hiv-medicine">https://press.asimov.com/articles/hiv-medicine</a> </li><li>Highly active antiretroviral therapy transformed the lives of people with HIV — Dattani (2024) <a href="https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv">https://ourworldindata.org/data-insights/highly-active-antiretroviral-therapy-transformed-the-lives-of-people-with-hiv</a> </li></ul><p><br></p><p>Videos:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) <a href="https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum">https://www.youtube.com/watch?v=iZ9KDxV5Zbs&amp;ab_channel=NationalHIVCurriculum</a> <p></p></li></ul><p>Image credits:</p><ul><li>Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action — David Spach, National HIV Curriculum (2024) [Multiple diagrams of HIV capsid and lenacapavir’s effect.]</li><li>Saloni Dattani; Our World in Data (2024) Highly active antiretroviral therapy transformed the lives of people with HIV. [Graph of decline in HIV/AIDS mortality after HAART was introduced.]</li><li>Engelman and Cherepanov (2012). The structural biology of HIV-1: mechanistic and therapeutic insights. [Diagram of HIV’s entry into the cell.]</li><li>Susan Moir, Tae-Wook Chun, Anthony S Fauci (2011). Pathogenic mechanisms of HIV disease. [Diagram of HIV replication rates over time, contrasting acute and chronic infection.]</li><li>Saloni Dattani, adapted from Patel et al. (2014). Estimating per-act HIV transmission risk: a systematic review. [Bar chart of risks of contracting HIV from different sources when unprotected.]</li><li>Thomas Splettstoesser under CC-BY. [Diagram of HIV’s internal structure.]</li><li>Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women — Bekker et al. (2024) [Chart of lenacapavir’s efficacy.]</li><li>Our World in Data based on Joint United Nations Programme on HIV/AIDS (2024). [Chart of global HIV deaths over time.]<p></p></li></ul><p>Acknowledgements:</p><ul><li>Douglas Chukwu, researcher at Open Philanthropy</li><li>Sanela Rankovic, Acting Instructor at the Institute for...</li></ul>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, Global Health, Science, Technology</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
      <podcast:transcript url="https://share.transistor.fm/s/a3753a45/transcript.txt" type="text/plain"/>
      <podcast:chapters url="https://share.transistor.fm/s/a3753a45/chapters.json" type="application/json+chapters"/>
    </item>
    <item>
      <title>Coming soon: Hard Drugs</title>
      <itunes:episode>1</itunes:episode>
      <podcast:episode>1</podcast:episode>
      <itunes:title>Coming soon: Hard Drugs</itunes:title>
      <itunes:episodeType>trailer</itunes:episodeType>
      <guid isPermaLink="false">2fc00d6f-956d-444f-986e-e5ac25375566</guid>
      <link>https://share.transistor.fm/s/a0398da8</link>
      <description>
        <![CDATA[<p>Hard Drugs is a new podcast about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most.</p><p>Presented and written by Saloni Dattani and Jacob Trefethen. Brought to you by Works in Progress and Open Philanthropy.</p>]]>
      </description>
      <content:encoded>
        <![CDATA[<p>Hard Drugs is a new podcast about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most.</p><p>Presented and written by Saloni Dattani and Jacob Trefethen. Brought to you by Works in Progress and Open Philanthropy.</p>]]>
      </content:encoded>
      <pubDate>Mon, 09 Jun 2025 12:59:56 +0100</pubDate>
      <author>Saloni Dattani &amp; Jacob Trefethen</author>
      <enclosure url="https://media.transistor.fm/a0398da8/3215e0da.mp3" length="2400175" type="audio/mpeg"/>
      <itunes:author>Saloni Dattani &amp; Jacob Trefethen</itunes:author>
      <itunes:duration>59</itunes:duration>
      <itunes:summary>
        <![CDATA[<p>Hard Drugs is a new podcast about medical innovation: how to speed it up, how to scale it up, and how to make sure lifesaving tools reach the people who need them the most.</p><p>Presented and written by Saloni Dattani and Jacob Trefethen. Brought to you by Works in Progress and Open Philanthropy.</p>]]>
      </itunes:summary>
      <itunes:keywords>Medicine, Global Health, Science, Technology</itunes:keywords>
      <itunes:explicit>No</itunes:explicit>
    </item>
  </channel>
</rss>
